Retrospective study of anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment for patients with advanced pancreatic adenocarcinoma
Latest Information Update: 02 Mar 2022
At a glance
- Drugs Catequentinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 02 Mar 2022 New trial record
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium